Cansortium Inkomsten in het verleden
Verleden criteriumcontroles 0/6
Cansortium has been growing earnings at an average annual rate of 15.3%, while the Pharmaceuticals industry saw earnings growing at 46% annually. Revenues have been growing at an average rate of 25.9% per year.
Belangrijke informatie
15.3%
Groei van de winst
25.6%
Groei van de winst per aandeel
| Pharmaceuticals Groei van de industrie | 23.1% |
| Inkomstengroei | 25.9% |
| Rendement op eigen vermogen | -230.1% |
| Nettomarge | -12.8% |
| Laatste winstupdate | 30 Jun 2024 |
Recente prestatie-updates uit het verleden
Recent updates
Cansortium (CSE:TIUM.U) Seems To Be Using A Lot Of Debt
Oct 25
Cansortium Inc. (CSE:TIUM.U) Soars 30% But It's A Story Of Risk Vs Reward
Sep 04Cansortium Inc.'s (CSE:TIUM.U) CEO Compensation Is Looking A Bit Stretched At The Moment
Aug 21Slammed 32% Cansortium Inc. (CSE:TIUM.U) Screens Well Here But There Might Be A Catch
Jul 11Cansortium Inc.'s (CSE:TIUM.U) Shares Not Telling The Full Story
Jan 15Is Cansortium (CSE:TIUM.U) Using Too Much Debt?
Nov 30Is Cansortium (CSE:TIUM.U) Using Debt Sensibly?
Sep 01Cansortium Inc. (CSE:TIUM.U) Looks Inexpensive After Falling 30% But Perhaps Not Attractive Enough
Jul 28An Intrinsic Calculation For Cansortium Inc. (CSE:TIUM.U) Suggests It's 26% Undervalued
Mar 08Does Cansortium (CSE:TIUM.U) Have A Healthy Balance Sheet?
Jan 09Here's Why Cansortium (CSE:TIUM.U) Has A Meaningful Debt Burden
Sep 09Opbrengsten en kosten
Hoe Cansortium geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
| Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
|---|---|---|---|---|
| 30 Jun 24 | 103 | -13 | 36 | 0 |
| 31 Mar 24 | 100 | -20 | 34 | 0 |
| 31 Dec 23 | 97 | -23 | 31 | 0 |
| 30 Sep 23 | 95 | -36 | 29 | 0 |
| 30 Jun 23 | 92 | -36 | 28 | 0 |
| 31 Mar 23 | 90 | -34 | 26 | 0 |
| 31 Dec 22 | 88 | -37 | 26 | 0 |
| 30 Sep 22 | 83 | -15 | 27 | 0 |
| 30 Jun 22 | 76 | -2 | 27 | 0 |
| 31 Mar 22 | 70 | -24 | 27 | 0 |
| 31 Dec 21 | 65 | -19 | 30 | 0 |
| 30 Sep 21 | 62 | -31 | 32 | 0 |
| 30 Jun 21 | 61 | -47 | 33 | 0 |
| 31 Mar 21 | 57 | -28 | 35 | 0 |
| 31 Dec 20 | 52 | -37 | 32 | 0 |
| 30 Sep 20 | 47 | -48 | 35 | 0 |
| 30 Jun 20 | 40 | -51 | 35 | 0 |
| 31 Mar 20 | 33 | -51 | 35 | 0 |
| 31 Dec 19 | 29 | -53 | 41 | 0 |
| 30 Sep 19 | 24 | -54 | 41 | 0 |
| 30 Jun 19 | 19 | -13 | 39 | 0 |
| 31 Mar 19 | 14 | -9 | 33 | 0 |
| 31 Dec 18 | 8 | 0 | 21 | 0 |
| 30 Sep 18 | 3 | 16 | 14 | 0 |
| 30 Jun 18 | 0 | -15 | 9 | 0 |
| 31 Mar 18 | 0 | -16 | 8 | 0 |
| 31 Dec 17 | 0 | -10 | 8 | 0 |
Kwaliteitswinsten: TIUM.U is currently unprofitable.
Groeiende winstmarge: TIUM.U is currently unprofitable.
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: TIUM.U is unprofitable, but has reduced losses over the past 5 years at a rate of 15.3% per year.
Versnelling van de groei: Unable to compare TIUM.U's earnings growth over the past year to its 5-year average as it is currently unprofitable
Winst versus industrie: TIUM.U is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-40.8%).
Rendement op eigen vermogen
Hoge ROE: TIUM.U has a negative Return on Equity (-230.12%), as it is currently unprofitable.